🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06962696
Recruiting Observational

Assessing the Performance of GPT-4o in Evaluating the Safety of Home Environment for Older Adults

NCT06962696 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2025-03-01
Last updated
2025-06-22

Condition(s) studied

Elderly (People Aged 65 or More)Home Environment Related Disease

Investigational drug(s) / intervention(s)

No intervention

No intervention: no intervention provided

Study summary

This study is an investigative study, taking the elderly in Beijing community as an example, and taking photos of different areas in the home environment of the elderly who agree to participate in the study (a total of seven aspects, including pathways/entrance to home, hallways, stairs/steps, living room, kitchen, restroom, bedroom). Subsequently, the multi-modal large model GPT-4o and a professional occupational therapist will use the "Home Environment Assessment" scale to evaluate the home environment shown in the photos and give corresponding suggestions for modification. A professional occupational therapist (non-evaluator) will analyze and compare the evaluation results and guidance recommendations of GPT-4o and the evaluator, and compare whether there are any significant differences between the two analysis results.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age ≥65 years old 2. Staying in the place of residence for a long time 3. Having normal listening, speaking, and comprehension skills Exclusion Criteria: Does not live regularly in the place of residence

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing Beijing Municipality Recruiting

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06962696 on ClinicalTrials.gov ↗ ← All trials in China